ExeVir Bio Looks To Llamas To Tackle Coronavirus Crisis
Raises €23m From Belgium-Based Backers
UCB and Fund+ are supporting a spin out from the renowned VIB research institute and ExeVir Bio CEO Torsten Mummenbrauer told Scrip that the firm's llama antibodies should be in the clinic for COVID-19 possibly by November.
